NASDAQ:NBSE NeuBase Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NeuBase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.85 -0.04 (-4.49%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$0.79▼$0.9850-Day Range$0.82▼$1.5052-Week Range$0.79▼$5.45Volume63,513 shsAverage Volume50,415 shsMarket Capitalization$27.42 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NBSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NBSE Stock Forecast (MarketRank)Overall MarketRank™2.30 out of 5 starsMedical Sector277th out of 1,411 stocksPharmaceutical Preparations Industry112th out of 672 stocksAnalyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingNeuBase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, NeuBase Therapeutics has a forecasted upside of 1,017.6% from its current price of $0.85.Amount of Analyst CoverageNeuBase Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.3 Community Rank Outperform VotesNeuBase Therapeutics has received 48 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeuBase Therapeutics has received 28 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeuBase Therapeutics has received 63.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NeuBase Therapeutics and other stocks. Vote “Outperform” if you believe NBSE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBSE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeuBase Therapeutics does not currently pay a dividend.Dividend GrowthNeuBase Therapeutics does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuBase Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,904.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.20% of the stock of NeuBase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.30% of the stock of NeuBase Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NeuBase Therapeutics are expected to grow in the coming year, from ($1.14) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuBase Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuBase Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuBase Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NeuBase Therapeutics (NASDAQ:NBSE)NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Read More NBSE Stock News HeadlinesJune 10, 2022 | americanbankingnews.com-$0.30 EPS Expected for NeuBase Therapeutics, Inc. (NASDAQ:NBSE) This QuarterJune 3, 2022 | americanbankingnews.comNeuBase Therapeutics (NASDAQ:NBSE) Lifted to Hold at Zacks Investment ResearchJune 1, 2022 | apnews.comNeuBase to Participate at the Jefferies Healthcare ConferenceJune 1, 2022 | finance.yahoo.comNeuBase to Participate at the Jefferies Healthcare ConferenceJune 1, 2022 | americanbankingnews.comNeuBase Therapeutics (NASDAQ:NBSE) Given New $10.00 Price Target at HC WainwrightMay 17, 2022 | finance.yahoo.comNeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment SolutionMay 13, 2022 | seekingalpha.comNeuBase Therapeutics GAAP EPS of -$0.30 misses by $0.06May 13, 2022 | finance.yahoo.comNeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022May 12, 2022 | finance.yahoo.comInsiders who bought in the last 12 months lose an additional US$65k as NeuBase Therapeutics, Inc. (NASDAQ:NBSE) drops to US$29mMay 2, 2022 | finance.yahoo.comNeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual MeetingMarch 14, 2022 | finance.yahoo.comNeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia ReversalMarch 7, 2022 | finance.yahoo.comNeuBase to Present at Oppenheimer’s 32nd Annual Healthcare ConferenceMarch 7, 2022 | finance.yahoo.comNeuBase to Present at Oppenheimer’s 32nd Annual Healthcare ConferenceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBSE CUSIPN/A CIK1173281 Webwww.neubasetherapeutics.com Phone(164) 645-1790FaxN/AEmployees33Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/26/2022Next Earnings (Estimated)8/11/2022Fiscal Year End9/30/2022Price Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$10.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+1,017.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-66.97% Return on Assets-55.86% Debt Debt-to-Equity RatioN/A Current Ratio8.07 Quick Ratio8.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book0.52Miscellaneous Outstanding Shares32,260,000Free Float27,356,000Market Cap$27.42 million OptionableNot Optionable Beta0.79 NeuBase Therapeutics Frequently Asked Questions Should I buy or sell NeuBase Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NeuBase Therapeutics stock. View analyst ratings for NeuBase Therapeutics or view top-rated stocks. What is NeuBase Therapeutics' stock price forecast for 2022? 1 brokerages have issued twelve-month price objectives for NeuBase Therapeutics' shares. Their NBSE stock forecasts range from $9.00 to $10.00. On average, they predict NeuBase Therapeutics' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 1,017.6% from the stock's current price. View analysts' price targets for NeuBase Therapeutics or view top-rated stocks among Wall Street analysts. How has NeuBase Therapeutics' stock performed in 2022? NeuBase Therapeutics' stock was trading at $2.81 at the start of the year. Since then, NBSE stock has decreased by 69.8% and is now trading at $0.85. View the best growth stocks for 2022 here. When is NeuBase Therapeutics' next earnings date? NeuBase Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for NeuBase Therapeutics. How were NeuBase Therapeutics' earnings last quarter? NeuBase Therapeutics, Inc. (NASDAQ:NBSE) posted its quarterly earnings results on Thursday, May, 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. View NeuBase Therapeutics' earnings history. Who are NeuBase Therapeutics' key executives? NeuBase Therapeutics' management team includes the following people: Dr. Dietrich A. Stephan Ph.D., Founder, Pres, CEO & Chairman (Age 52, Pay $713.83k) (LinkedIn Profile)Dr. William Roland Mann MBA, Ph.D., Chief Operating Officer (Age 62, Pay $470.4k)Mr. Todd P. Branning, Chief Financial Officer (Age 51)Dr. Anthony Rossomando Ph.D., Chief Technology OfficerDr. Curt Bradshaw Ph.D., Chief Scientific Officer (Age 57)Mr. Alan Scrivner J.D., VP of IP & LegalMs. Shannon McCarthy, Chief People OfficerDr. Sandra Rojas-Caro M.D., Head of R&D and Chief Medical Officer (Age 52)Dr. Robert J. Zamboni Ph.D., Chief of Preclinical Devel. & Member of Scientific Advisory Board Who are some of NeuBase Therapeutics' key competitors? Some companies that are related to NeuBase Therapeutics include Daré Bioscience (DARE), Leap Therapeutics (LPTX), PDS Biotechnology (PDSB), Praxis Precision Medicines (PRAX), Cue Biopharma (CUE), Entasis Therapeutics (ETTX), Assembly Biosciences (ASMB), RVL Pharmaceuticals (RVLP), Vascular Biogenics (VBLT), ImmunoPrecise Antibodies (IPA), Xynomic Pharmaceuticals (XYNO), Checkpoint Therapeutics (CKPT), Clearside Biomedical (CLSD), Rain Therapeutics (RAIN) and 9 Meters Biopharma (NMTR). View all of NBSE's competitors. What other stocks do shareholders of NeuBase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV). What is NeuBase Therapeutics' stock symbol? NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE." Who are NeuBase Therapeutics' major shareholders? NeuBase Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.23%), AIGH Capital Management LLC (3.14%), Decheng Capital Management III Cayman LLC (3.05%), CM Management LLC (0.99%), Worth Venture Partners LLC (0.80%) and Renaissance Technologies LLC (0.66%). Company insiders that own NeuBase Therapeutics stock include Dietrich A Stephan, Eric I Richman, Samuel Backenroth, Todd P Branning and William Roland Mann. View institutional ownership trends for NeuBase Therapeutics. Which institutional investors are selling NeuBase Therapeutics stock? NBSE stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View insider buying and selling activity for NeuBase Therapeutics or view top insider-selling stocks. Which institutional investors are buying NeuBase Therapeutics stock? NBSE stock was purchased by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, CM Management LLC, Renaissance Technologies LLC, Waldron Private Wealth LLC, Royal Bank of Canada, Perkins Capital Management Inc., Worth Venture Partners LLC, and AIGH Capital Management LLC. Company insiders that have bought NeuBase Therapeutics stock in the last two years include Dietrich A Stephan, Eric I Richman, Todd P Branning, and William Roland Mann. View insider buying and selling activity for NeuBase Therapeutics or or view top insider-buying stocks. How do I buy shares of NeuBase Therapeutics? Shares of NBSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NeuBase Therapeutics' stock price today? One share of NBSE stock can currently be purchased for approximately $0.85. How much money does NeuBase Therapeutics make? NeuBase Therapeutics (NASDAQ:NBSE) has a market capitalization of $27.42 million. The company earns $-25.41 million in net income (profit) each year or ($1.04) on an earnings per share basis. How many employees does NeuBase Therapeutics have? NeuBase Therapeutics employs 33 workers across the globe. How can I contact NeuBase Therapeutics? NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The official website for NeuBase Therapeutics is www.neubasetherapeutics.com. The company can be reached via phone at (164) 645-1790 or via email at [email protected]. This page (NASDAQ:NBSE) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
